Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.45 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21025153 | 0.88 | KDM4E (0.47) | KDM4EKMT2ARXFP1TDP1MEN1 | |
| SCHEMBL20808718 | 0.84 | LMNA (0.55) | KDM4EKMT2ARXFP1TDP1MEN1 | |
| SCHEMBL20786895 | 0.82 | PSMB1 (0.61) | KDM4EKMT2ARXFP1TDP1MEN1 | |
| SCHEMBL21025554 | 0.82 | ITGB3 (0.42) | KDM4EKMT2APSMB1PSMB5ALDH1A1 | |
| SCHEMBL21025538 | 0.80 | GRM2 (0.40) | KDM4EKMT2AMEN1MAPTRAB9A | |
| SCHEMBL21025176 | 0.80 | GRIN2B (0.40) | KDM4EMAPT | |
| SCHEMBL28061868 | 0.72 | METAP2 (0.44) | KMT2AMEN1 | |
| SCHEMBL21025688 | 0.71 | NR1I2 (0.39) | ALDH1A1RAB9A | |
| SCHEMBL20808984 | 0.70 | LMNA (0.52) | KDM4EKMT2ARXFP1TDP1MEN1 | |
| SCHEMBL21025559 | 0.70 | GRM2 (0.40) | KMT2AMEN1MAPTPOLBRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10669252-B2 | Benzazepine derivative, preparation method, pharmaceutical composition and use thereof | Shanghai De Novo Pharmatech Co., Ltd. (CN) | 2020-06-02 | — | — | US | disclosed |
| US-20190152941-A1 | BENZAZEPINE DERIVATIVE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Shanghai De Novo Pharmatech Co., Ltd. (CN) | 2019-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10669252-B2 | Benzazepine derivative, preparation method, pharmaceutical composition and use thereof | TLR8, TLR1, TLR5 | KDM4E 1342/4885KMT2A 751/4885RXFP1 739/4885 |
| US-20190152941-A1 | BENZAZEPINE DERIVATIVE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | TLR8, TLR1, TLR5 | KDM4E 1342/4885KMT2A 751/4885RXFP1 739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.